Zimbabwe has declined a significant US healthcare agreement valued at $367m (272 million pounds) over five years over the United States' request for sensitive information.
This rejection became public after a internal memorandum dated December was leaked, revealing that President Emmerson Mnangagwa deemed the deal was "skewed".
A government spokesperson later explained that the US was demanding access to genetic material for research and commercial purposes but was unwilling to guarantee the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for continued negotiations to reach a deal acceptable to both sides so the nation's critical HIV programme can continue.
Broader Context
This rejection follows a comparable situation in Kenya, where a court suspended a similar health funding agreement following legal challenges were filed about the security of citizens' medical information.
Since resuming office last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had administered assistance for the American government, but Trump stated its spending was "inefficient" and his administration was seeking government-to-government deals to boost openness and accountability.
As per statements, 16 African countries have so far agreed to similar agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation could have provided immense advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving antiretroviral therapy through US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, with no equivalent promise of access to any medical innovations – like new medicines or tests – that could result from that provided information," Mangwana explained.
"In essence, our nation would supply the raw materials for scientific discovery with no certainty that the resulting innovations would be available to our population should a future pandemic arise."
National Interest and International Frameworks
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were upending systems already established via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This mechanism is intended to guarantee that when a nation contributes its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to develop them."
These objections regarding the US deal "are not meant as hostility towards the US," he added.
"We encourage ongoing discussions with our US partners on how future co-operation might be arranged in a way that honours the sovereignty and dignity of each country."
Health Experts Response
Medical experts said it acknowledged the government's concerns, but urged that negotiations need to persist given that a large portion of the country's HIV programmes depended on foreign aid.
"If technical issues arise, including those involving data governance or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," it said.
This impasse emphasises the continuing tensions between receiving crucial international aid and safeguarding national sovereignty in an increasingly interconnected world.